HLA-A2-restricted gp100 and tyrosinase peptide-MHC complexes (HLA-A2/gp100/TYR)

This target refers to the presentation of specific melanoma-associated antigens, gp100 and tyrosinase, via the HLA-A2 major histocompatibility complex on autologous dendritic cells [1, 2]. Gp100 (PMEL) and tyrosinase are key proteins involved in melanogenesis that are frequently overexpressed in malignant melanoma cells [1, 2]. In this therapeutic context, autologous dendritic cells are harvested from a patient, loaded with synthetic peptide epitopes of these antigens, and re-infused to act as professional antigen-presenting cells [3, 4]. The primary biological function of this complex is to prime and activate CD8+ cytotoxic T lymphocytes (CTLs) to recognize and kill tumor cells expressing these specific antigens [4, 5]. This strategy is designed to bypass the immune evasion mechanisms of tumors by providing a high-density display of antigens in a highly immunostimulatory environment [3]. Clinical use is restricted to patients who are HLA-A2 positive, as the specific peptides used are designed to bind only to this MHC allele [5]. The interaction between the dendritic cell-presented peptides and the T-cell receptor (TCR) is the critical step in initiating the anti-tumor response [4]. Therapeutic challenges include the potential for off-target autoimmune reactions against healthy melanocytes, often manifesting as vitiligo [5]. This target represents a personalized medicine approach in oncology, specifically for advanced or metastatic melanoma [3, 5].

Other names

gp100/tyrosinase-pulsed autologous dendritic cell vaccineMelanoma antigen-loaded autologous dendritic cellsHLA-A*0201 restricted melanoma peptide epitopesPMEL and TYR peptide-MHC complexes

Induction of tumor-specific cytotoxic T-lymphocyte (CTL) responses against melanoma cells expressing gp100 and tyrosinase antigens.